Meeting Introduction
On the afternoon of July 22, 2026, Anhui Poly Pharm Co., Ltd. held its mid-year work summary meeting. Heads of each module, closely aligning with the Group's strategic goals, delivered in-depth reports to the Plant Director of Anhui Poly Pharm based on core operational data, comprehensively reviewing the achievements and shortcomings of the first half of the year and quantifying and refining work measures for the second half.
Relying on 3 production workshops compliant with European, American, and Chinese GMP standards and 11 production lines, the mid-year summary reported core data including monthly output value and capacity utilization rate, with the first-pass qualification rate remaining stable above 99.7%. The production side emphasized that it must not only complete orders with quality and quantity guaranteed, but also have the confidence for "first-pass qualification." In the first half of the year, it continued to implement cost reduction and efficiency improvement measures, optimizing production scheduling and cost control.
The meeting reviewed the quality system development and audit reception work in the first half of the year. Despite limited staffing and a heavy workload, the team completed all quality tasks with both quality and quantity assured, which deserves full recognition. In response to future market access requirements in Europe and the United States, the quality team will continue to improve quality standards and system control capabilities, laying a solid quality foundation for expansion into high-end markets.
Focusing on products under development and commercialized varieties, the team continued to optimize process routes, improve product yield and production stability, and reduce manufacturing costs. Each project has defined process optimization targets and key milestones for the second half of the year, fully supporting production quality improvement and efficiency enhancement. The progress and milestone completion of projects under development were reviewed item by item, with full efforts to promote the industrialization of achievements.
The meeting reviewed the operation of the safety and environmental protection system in the first half of the year and clarified that in the second half, the frequency of safety regulation publicity and implementation will continue to be increased, multi-level safety case training will be carried out, and the safety awareness and emergency response capabilities of all employees will be comprehensively enhanced to build a solid defense line for safe production.
In-depth root cause analysis was conducted for equipment failures, and continuous efforts were made to advance institutional improvements and the development of a preventive maintenance system. In the first half of the year, the division's skilled personnel training achieved notable results, providing strong support for the efficient and stable operation of equipment.
Procurement, Finance, HR, and Administration each fulfilled their respective responsibilities: the Procurement Department, based on its function of ensuring production supply, coordinated material procurement in line with production progress to ensure a continuous and stable supply of materials required for production; the Finance side reviewed compliance rectification, tax planning, and financing results, and clarified plans for refined capital management and SOP system development in the second half of the year; the HR side reviewed headcount control and performance assessment, and formulated plans for personnel optimization and performance system iteration; the Administration side reviewed the compliance system and institutional implementation, and clarified specific measures for compliance training and refined management improvement in the second half of the year, providing all-round support for efficient business operations. The entire company closely centered on the company's core production goals, firmly established the work philosophy of "serving the front line and safeguarding production," and continuously strengthened supporting capabilities.
Meeting Conclusion
In his summary, Plant Director Li emphasized that in the first half of the year, all departments tackled difficulties head-on, closely focusing on production and operation goals, and achieved phased results in various areas of work. However, objectively speaking, we still face considerable pressure, and there is still obvious room for improvement in production efficiency, internal coordination, and refined management. Plant Director Li required all employees to strengthen their overall awareness, unite as one, and go all out to sprint toward the annual targets and tasks, driving the company's overall operating situation to continue improving.
Anhui Poly Pharm Co., Ltd., founded in 2018, is located in the Anqing National High-tech Industrial Development Zone. It is a professional supplier of active ingredients, providing high-quality specialty raw materials through chemical synthesis and biosynthesis to the global pharmaceutical, healthcare, and skincare industries.
Anhui Poly Pharm boasts a strong and efficient R&D and production team, is equipped with modern production facilities, and has established a strict cGMP quality system for high-end APIs in Europe and the United States, as well as a high-standard EHS system. While providing customers with high-quality APIs and intermediates, it also offers CDMO services, process technology upgrades, and more. The company currently has 3 API production workshops compliant with European, American, and Chinese GMP standards, 10 production lines, and 357 multi-functional pieces of equipment.
Leveraging strong R&D capabilities and technology transformation capabilities, the company has completed the commercial R&D and production of a series of products, including contrast agents (gadoterate meglumine, gadoteridol, gadobutrol, iomeprol, iopromide, ioversol, iopamidol, iodixanol, etc.), synthetic biology products (semaglutide, ectoine, salidroside), antitumor drugs (cyclophosphamide), other APIs (magnesium hydroxide, apremilast, crisaborole, voriconazole, memantine hydrochloride), and other pharmaceutical excipients (DOTA, SNAC, sodium sulfobutyl ether-β-cyclodextrin, calcium catelidol, cobiprostone calcium).
Welcome to Inquire — Let's Work Together!
Business Contact: lisubin@hnpoly.com
